Abeona Therapeutics Inc vs US Global Jets ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while US Global Jets ETF trades at $31.77. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | JETS | |
|---|---|---|
Market Cap | $424.33M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.45 | $33.53 |
52-Week Low | $4.17 | $23.64 |
Enterprise Value | $279.23M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
JETS trades at $32.54, down 0.31% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent news highlights mixed sentiment, including JetBlue's earnings beat lifting airline stocks but fuel cost pressures and geopolitical risks weighing on the sector. The ETF faces volatility from oil price swings and competitive ETF comparisons.
Outlook is cautious due to high sensitivity to fuel costs and travel demand cycles. Opportunities exist if oil remains low, but risks from Middle East tensions and economic slowdowns could pressure earnings. Investors should weigh JETS' cyclical nature against broader aerospace ETFs for diversification.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →